PCOS statistics: prevalence, diagnosis rates, and the cost of being overlooked

The first patient I diagnosed with PCOS had already been told by two doctors that her irregular periods were stress-related and that her weight gain was a personal discipline problem. She was 26. By the time I saw her, she had been experiencing symptoms for nearly a decade. Her story is unremarkable in the clinical sense — which is exactly the problem.

Polycystic ovary syndrome is the most common endocrine disorder affecting women of reproductive age. The CDC estimates it affects 6% to 12% of U.S. women, which puts the number somewhere between 5 and 6 million. And yet, by most estimates, the majority of those women do not know they have it.

This article covers what the data says about how many women have PCOS, why so many go undiagnosed, what the condition costs in both health and dollars, and why research funding has not matched the scale of the problem.

How many women have PCOS

Pinning down a single prevalence number for PCOS is harder than it should be, because the answer depends heavily on which diagnostic criteria you use and which population you study.

The CDC cites a range of 6% to 12% of U.S. women of reproductive age. A 2016 systematic review and meta-analysis by Bozdag and colleagues, published in Human Reproduction, analyzed 33 studies involving more than 90,000 women and concluded that overall prevalence ranges from 6% to 21%, depending on diagnostic criteria. When the older NIH criteria are applied (which require both hyperandrogenism and ovulatory dysfunction), prevalence lands around 6% to 9%. Under the broader Rotterdam criteria, which allow for more phenotypic combinations, prevalence reaches 15% to 21%.

A 2005 study by Azziz and colleagues screened 400 consecutive women presenting for routine blood donation in Alabama (women who were not seeking care for any hormonal complaint) and found that 6.6% met NIH criteria for PCOS. When Rotterdam criteria were applied to the same group, the number climbed to 15.3%.

Globally, PCOS is estimated to affect between 116 million and 280 million women, depending on which prevalence figure you accept. The condition exists in every geographic region and across all racial and ethnic groups, though reporting rates vary significantly by country.

The diagnosis problem

The 2023 International Evidence-based Guideline for the Assessment and Management of PCOS, led by Monash University and endorsed by over 40 international societies, stated that up to 70% of women with PCOS globally remain undiagnosed. That is not a typo. Seven out of ten.

Why? Several reasons compound on each other.

First, the symptoms of PCOS (irregular periods, acne, weight gain, hair growth on the face or body, thinning hair on the scalp) are individually common and are often attributed to other causes or dismissed entirely. Women report being told their irregular cycles are "normal variation" or that they just need to lose weight. The weight advice is especially corrosive because it frames a symptom of the condition as its cause.

Second, many primary care physicians are not confident in diagnosing PCOS. A survey of Australian GPs found that only 36% felt comfortable making the diagnosis. Training on PCOS in medical school is often limited to a few lectures. The result is that women cycle through multiple appointments before someone considers the correct diagnosis.

Third, the diagnostic criteria themselves have created confusion. Three different sets of criteria exist — the NIH criteria (1990), the Rotterdam criteria (2003), and the Androgen Excess Society criteria (2006). They overlap but are not identical, and the lack of a single agreed-upon standard has muddied clinical practice for decades.

If you have irregular periods and are unsure whether your cycle is within a normal range, our period calculator and cycle length calculator can help you track patterns to bring to your doctor.

What the Rotterdam criteria actually require

The Rotterdam criteria, which are the most widely used, require that a patient meet at least two of the following three conditions:

1. Oligo-ovulation or anovulation (irregular or absent ovulation)
2. Clinical or biochemical signs of hyperandrogenism (excess male-pattern hair growth, acne, or elevated androgen levels on blood tests)
3. Polycystic ovarian morphology on ultrasound (12 or more follicles per ovary, or ovarian volume greater than 10 mL)

The 2023 international guideline reaffirmed the Rotterdam criteria but made an important update: anti-Müllerian hormone (AMH) levels can now be used as an alternative to ultrasound for identifying polycystic ovarian morphology in adults. This matters because ultrasound quality varies by facility and operator, and AMH is a simple blood test. The guideline also noted that ultrasound should not be used for diagnosis within 8 years of menarche, because polycystic-appearing ovaries are common in adolescents and are often a normal developmental variant.

One thing the Rotterdam criteria do not require: actual cysts. The "cysts" in PCOS are follicles, which are fluid-filled sacs containing immature eggs. They are not pathological cysts in the traditional sense. The name itself is misleading, and there have been periodic calls to rename the condition — calls that have not yet succeeded.

PCOS and insulin resistance

Insulin resistance is the metabolic thread that runs through most cases of PCOS. Between 50% and 70% of women with PCOS have some degree of insulin resistance, regardless of body weight. This is a critical point: insulin resistance in PCOS is not simply a consequence of being overweight. Lean women with PCOS have higher rates of insulin resistance than weight-matched women without the condition.

The mechanism works like this: when cells become less responsive to insulin, the body compensates by producing more of it. Elevated insulin stimulates the ovaries to produce excess androgens, which disrupts follicle development and ovulation. At the same time, excess insulin promotes fat storage, particularly visceral fat, which further worsens insulin resistance. It is a feedback loop.

The downstream consequences are serious. Women with PCOS are 2 to 4 times more likely to develop type 2 diabetes than women without PCOS, according to the CDC. The risk is highest in women with a BMI over 30, but it exists at all body sizes. Up to 40% of women with PCOS will develop prediabetes or type 2 diabetes by age 40.

Metformin, a medication originally developed for type 2 diabetes, is widely used off-label in PCOS management to improve insulin sensitivity. The 2023 international guideline recommends considering metformin for metabolic outcomes in PCOS, though it notes that the evidence for its effect on weight loss is modest — typically 1 to 3 kg over 6 months.

Dietary management plays a significant role. Our PCOS diet guide covers the nutritional strategies that have the strongest evidence behind them.

Long-term health risks

PCOS is not just a reproductive condition. It is a metabolic syndrome with implications that extend well beyond fertility.

Beyond the diabetes risk already mentioned, women with PCOS have a 2-fold increased risk of cardiovascular events (heart attack, stroke) over their lifetime. They have elevated rates of dyslipidemia, with higher triglycerides and lower HDL cholesterol. They have a 2- to 6-fold increased risk of endometrial cancer, driven by chronic anovulation and the resulting unopposed estrogen exposure of the uterine lining.

Mental health is also significantly affected. Women with PCOS are 3 times more likely to be diagnosed with depression and 5 times more likely to be diagnosed with anxiety compared to women without PCOS, according to a meta-analysis published in Human Reproduction. Eating disorders, particularly binge eating disorder, are more prevalent in PCOS populations.

Sleep apnea occurs at elevated rates, even in women who are not overweight. A study published in the Journal of Clinical Endocrinology & Metabolism found that women with PCOS have a 5- to 30-fold higher risk of obstructive sleep apnea compared to age- and BMI-matched controls.

The 2023 international guideline emphasized that screening for cardiovascular risk factors and mental health should be routine in PCOS care, not an afterthought. In practice, many clinicians focus on the reproductive symptoms and do not assess the broader metabolic picture.

The financial burden

A 2022 study by Riestenberg and colleagues, published in the Journal of Clinical Endocrinology & Metabolism, estimated the total annual healthcare cost attributable to PCOS in the United States at $4.3 billion. That figure includes direct medical costs from diagnosis, treatment, and management of PCOS-related comorbidities — diabetes, cardiovascular disease, endometrial cancer, infertility treatment, and mental health care.

At the individual level, women with PCOS incur approximately $5,000 to $8,000 more in annual healthcare costs than women without the condition. These costs accumulate across a lifetime, often beginning in adolescence.

The economic burden is also shaped by what PCOS does to fertility. Approximately 70% to 80% of women with PCOS experience difficulty conceiving. For those who pursue assisted reproduction, a single IVF cycle in the United States costs $15,000 to $25,000 on average, and many women require multiple cycles. Insurance coverage for fertility treatment varies dramatically by state, and in many states, it is nonexistent.

Indirect costs (lost work productivity, reduced quality of life, the psychological toll of managing a chronic condition that many people have never heard of) are harder to quantify but no less real.

PCOS and fertility

PCOS is the most common cause of anovulatory infertility. When ovulation does not occur regularly, conception becomes difficult or impossible without intervention. But here is what often gets lost in the conversation: most women with PCOS can become pregnant with appropriate treatment.

First-line treatment for ovulatory dysfunction in PCOS is letrozole (an aromatase inhibitor), which the 2023 guideline recommends over clomiphene citrate based on evidence of higher live birth rates. Clomiphene remains an option, particularly where letrozole is not accessible, but several randomized trials have shown letrozole produces ovulation rates of 60% to 80% and live birth rates around 27% to 44% per treatment cycle.

For women who do not respond to oral medications, gonadotropin injections or ovarian drilling are second-line options. IVF is typically reserved for cases where other approaches have failed, or when additional factors like tubal disease or male factor infertility are present.

Weight management, when relevant, can make a significant difference. Studies have shown that a 5% to 10% reduction in body weight can restore regular ovulation in some women with PCOS. This is not about reaching a specific BMI target — it is about modest changes that shift the hormonal balance enough to improve ovulatory function.

If you are tracking ovulation while managing PCOS, our ovulation calculator and guide to ovulation symptoms may be useful, keeping in mind that cycle irregularity can make prediction less precise.

Research funding and the gap

PCOS affects more women than breast cancer, endometriosis, and rheumatoid arthritis combined. Research funding does not reflect that.

In fiscal year 2023, the NIH allocated approximately $61 million for PCOS research. That is an increase from prior years (in 2015, the figure was closer to $38 million) but it remains a small fraction of the NIH's overall budget of approximately $48 billion. Per-patient funding for PCOS comes to roughly $10 to $12 per affected woman per year.

For context: NIH funding for type 2 diabetes was approximately $2.1 billion in FY 2023, and type 2 diabetes affects about 37 million Americans. That comes to roughly $57 per affected person. The per-patient funding gap between PCOS and diabetes is roughly 5-fold, even though PCOS is a major risk factor for developing diabetes.

NIH research funding by condition, FY 2023. Source: NIH RCDC.

The 2023 international guideline explicitly called for increased research funding, noting that the evidence base for many aspects of PCOS management remains weak. Fundamental questions (what causes PCOS, whether it has a genetic basis that can be targeted therapeutically, how best to prevent its metabolic complications) remain poorly funded and insufficiently studied.

PCOS across race and ethnicity

PCOS occurs across all racial and ethnic groups, but the phenotypic presentation and associated metabolic risks vary.

A 2018 systematic review and meta-analysis by Ding and colleagues, published in Oncotarget, found that prevalence was broadly similar across populations when the same diagnostic criteria were applied. However, metabolic complications differ. South Asian women with PCOS have higher rates of insulin resistance and type 2 diabetes compared to white women with PCOS. Hispanic women with PCOS show higher rates of metabolic syndrome.

Black women with PCOS present less frequently with hirsutism (excess hair growth), which is one of the three Rotterdam criteria. This means that Black women who have PCOS but whose primary features are irregular cycles and insulin resistance may be less likely to meet clinical suspicion for the diagnosis if a provider is looking primarily for visible androgenic signs.

Diagnosis rates also vary by access. Women without insurance, women in rural areas, and women who primarily receive care through emergency departments rather than established primary care are less likely to receive a PCOS diagnosis. The condition requires blood tests, often an ultrasound, and a provider who is thinking about it. When any of those elements is missing, the diagnosis does not get made.

Frequently asked questions about PCOS statistics

How common is PCOS?

PCOS affects 6% to 12% of U.S. women of reproductive age, or approximately 5 to 6 million women, according to the CDC. Under the broader Rotterdam diagnostic criteria, prevalence may be as high as 15% to 21%. Globally, an estimated 116 to 280 million women have PCOS. It is the most common endocrine disorder in women of reproductive age.

Why do so many women with PCOS go undiagnosed?

Up to 70% of women with PCOS remain undiagnosed, per the 2023 international guideline led by Monash University. Diagnosis is delayed because symptoms like irregular periods and weight gain are often attributed to other causes, primary care training on PCOS is limited, and three different sets of diagnostic criteria have created clinical confusion. Women see an average of 3 to 4 doctors before receiving a PCOS diagnosis.

Does PCOS cause diabetes?

PCOS significantly increases diabetes risk. Between 50% and 70% of women with PCOS have insulin resistance, regardless of body weight. Women with PCOS are 2 to 4 times more likely to develop type 2 diabetes than women without the condition, according to the CDC. Up to 40% of women with PCOS will develop prediabetes or type 2 diabetes by age 40.

How much does PCOS cost the healthcare system?

The estimated annual healthcare cost attributed to PCOS in the United States is $4.3 billion, per a 2022 study published in the Journal of Clinical Endocrinology & Metabolism. Individual women with PCOS incur approximately $5,000 to $8,000 more in annual healthcare costs than women without the condition, including costs for managing comorbidities like diabetes, cardiovascular disease, and infertility treatment.

Can women with PCOS get pregnant?

Yes. While PCOS is the most common cause of anovulatory infertility, most women with PCOS can conceive with treatment. Letrozole is the recommended first-line medication, with ovulation rates of 60% to 80% per cycle. A 5% to 10% weight reduction can restore regular ovulation in some women. IVF is typically reserved for cases where other treatments have not been effective or when additional fertility factors are present.

How much research funding does PCOS receive?

The NIH allocated approximately $61 million for PCOS research in FY 2023, representing less than 0.13% of the total NIH budget. Per-patient funding is roughly $10 to $12 per affected woman per year. By comparison, type 2 diabetes receives approximately $57 per affected person in NIH funding. The 2023 international PCOS guideline explicitly called for increased research investment.